ArticleInfectious diseases and therapy2023

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.

F D Richard Hobbs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.